These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8825851)

  • 21. [Importance of corticoids in inhibitor suppression in hemophilia A, in addition to continuing treatment with factor VIII concentrate].
    Aznar JA; Jorquera JI; Marty ML
    Sangre (Barc); 1983; 28(3):265-79. PubMed ID: 6414098
    [No Abstract]   [Full Text] [Related]  

  • 22. [Use of fraction C-1 in children with hemophilia A].
    Kamińska D; Adamowicz-Salach A; Pytel Z
    Pediatr Pol; 1985 Jan; 60(1):65-8. PubMed ID: 3929224
    [No Abstract]   [Full Text] [Related]  

  • 23. [Elimination of inhibitors in children with hemophilia A].
    Weissbach G; Domula M; Lenk H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(6):817-25. PubMed ID: 6083958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Harrison JF; Bloom AL; Abildgaard CF
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):29-35; discussion 36. PubMed ID: 1908124
    [No Abstract]   [Full Text] [Related]  

  • 26. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Projected estimation of factor VIII requirements for home treatment based on a pilot study of two haemophilic patients.
    Davies SH
    Scand J Haematol Suppl; 1977; 30():87-9. PubMed ID: 267310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose requirement for replacement therapy in hemophilia A.
    Allain JP
    Thromb Haemost; 1979 Oct; 42(3):825-31. PubMed ID: 505399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimum effective dose of intermediate factor-VIII concentrate in haemophiliacs on home therapy.
    Stirling ML; Prescott RJ
    Lancet; 1979 Apr; 1(8120):813-4. PubMed ID: 86051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.
    von Auer Ch; Oldenburg J; von Depka M; Escuriola-Ettinghausen C; Kurnik K; Lenk H; Scharrer I
    Ann N Y Acad Sci; 2005 Jun; 1051():498-505. PubMed ID: 16126990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
    Schwartz RS; Abildgaard CF; Aledort LM; Arkin S; Bloom AL; Brackmann HH; Brettler DB; Fukui H; Hilgartner MW; Inwood MJ
    N Engl J Med; 1990 Dec; 323(26):1800-5. PubMed ID: 2123300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elective cardiac operation in a patient with severe hemophilia and acquired factor VIII antibodies.
    Leggett PL; Doyle D; Smith WB; Culpepper W; Cooper S; Ochsner JL
    J Thorac Cardiovasc Surg; 1984 Apr; 87(4):556-60. PubMed ID: 6423912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Perioperative management of ventricular septal defect and right coronary cusp prolapse in a patient with hemophilia A].
    Nomura K; Nakamura Y; Yamagishi M; Yamamoto K; Hanada R
    Kyobu Geka; 1994 Dec; 47(13):1071-4. PubMed ID: 7830356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience.
    Schulman S; Varon D; Keller N; Gitel S; Martinowitz U
    Thromb Haemost; 1994 Sep; 72(3):403-7. PubMed ID: 7855792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lyophilized cryoprecipitate for children with hemophilia A.
    Nuchprayoon I; Sahasittiwat S; Kittikalayawong A; Chantanakajornfung A
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S293-7. PubMed ID: 12188426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor products in the treatment of hemophilia.
    Miller KL
    J Pediatr Health Care; 2004; 18(3):156-7. PubMed ID: 15129219
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of plasma exchange in hereditary deficiency of factor V and factor VIII.
    Sallah AS; Angchaisuksiri P; Roberts HR
    Am J Hematol; 1996 Jul; 52(3):229-30. PubMed ID: 8756096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letter: Emergency domiciliary treatment for haemophilia.
    Leslie J; Taylor E
    Lancet; 1975 Feb; 1(7901):282-3. PubMed ID: 46430
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.